To explore the specific challenges faced by platform trials, including operational inefficiencies and regulatory barriers, and assess their compatibility with the current clinical trial system.
Key Findings:
The number of new platform trials has declined post-COVID-19, with many failing to add new arms, indicating a need for reevaluation of trial design.
Over 40% of launched platform trials are not functioning as intended, highlighting significant operational challenges.
Complex legal arrangements and regulatory landscapes are significant barriers to platform trial success, necessitating reform.
Interpretation:
The current clinical trial system is not well-suited for platform trials, leading to operational inefficiencies and high failure rates, which must be addressed for future success.
Limitations:
Low response rates in the survey limit the ability to generalize findings, potentially skewing the understanding of challenges.
The survey's purposive sampling may not capture the full spectrum of challenges, indicating a need for broader data collection.
Conclusion:
Sustainable funding mechanisms and strategic planning are essential to enhance the viability of platform trials and reduce failure rates, including the need for flexible funding models that support ongoing trial adaptations.
